{"disease":{"id":"advanced-solid-tumors-or-lymphomas","name":"advanced solid tumors or lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04458389","title":"A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":268,"lead_sponsor_name":"Tayu Huaxia Biotech Medical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05374226","title":"A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT02675439","title":"Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Chinook Therapeutics, Inc. (formerly Aduro)","has_results":false},{"nct_id":"NCT06073938","title":"Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}